标记染色体可源于染色体碎裂并预示急性髓系白血病不良预后
在AML96和AML2003两项前瞻性随机多中心强化化疗试验中,165/1026(16.1%)的非CBF异常核型AML患者可检出标记染色体,其与较低缓解率、较差无事件生存和总生存相关,多变量分析中为≤60岁患者独立不良预后因素;约三分之一标记染色体(18/49)经阵列比较基因组杂交证实源于染色体碎裂,后者与高度核型复杂、TP53突变和极差预后相关。
要点
- 非CBF异常核型AML中标记染色体检出率为16.1%(165/1026)。
- 标记染色体患者缓解率更低、无事件生存和总生存更差,在≤60岁患者中为独立预后因素。
- 约三分之一标记染色体(18/49)源于染色体碎裂,与TP53突变和极差预后相关。
核心结论
- 标记染色体提示染色体碎裂,其本身即与不良预后相关,而不仅仅是通过与其他不良细胞遗传学特征相关联。
研究设计与样本
- 研究基于Study Alliance Leukemia的两项大型连续前瞻性随机多中心强化化疗试验(AML96、AML2003),评估标记染色体的频率、细胞遗传学特征、预后影响和生物学起源。
- 在1026例非核心结合因子(CBF)异常核型患者中检出标记染色体165例(16.1%)。
主要发现
- 不良风险核型中标记染色体频率更高:不良风险核型26.5%、复杂异常核型40.3%、异常(17p)核型41.2%,各P < .0001。
- 标记染色体与其他非CBF异常核型相比预后更差,两项试验中均导致更低缓解率(完全缓解+完全缓解伴不完全恢复)、更差无事件生存和总生存。
- 多变量分析中,标记染色体在AML96试验≤60岁患者中独立预测不良预后。
- 阵列比较基因组杂交检测显示约三分之一标记染色体(18/49)源于染色体碎裂,而标记染色体阴性的复杂异常核型对照组中几乎检测不到(1/34)。
- 染色体碎裂阳性病例以核型复杂度特别高、TP53突变和极差预后为特征。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metaphase karyotyping is an established diagnostic standard in acute myeloid leukemia (AML) for risk stratification. One of the cytogenetic findings in AML is structurally highly abnormal marker chromosomes. In this study, we have assessed frequency, cytogenetic characteristics, prognostic impact, and underlying biological origin of marker chromosomes. Given their inherent gross structural chromosomal damage, we speculated that they may arise from chromothripsis, a recently described phenomenon of chromosome fragmentation in a single catastrophic event. In 2 large consecutive prospective, randomized, multicenter, intensive chemotherapy trials (AML96, AML2003) from the Study Alliance Leukemia, marker chromosomes were detectable in 165/1026 (16.1%) of aberrant non-core-binding-factor (CBF) karyotype patients. Adverse-risk karyotypes displayed a higher frequency of marker chromosomes (26.5% in adverse-risk, 40.3% in complex aberrant, and 41.2% in abnormality(17p) karyotypes, P < .0001 each). Marker chromosomes were associated with a poorer prognosis compared with other non-CBF aberrant karyotypes and led to lower remission rates (complete remission + complete remission with incomplete recovery), inferior event-free survival as well as overall survival in both trials. In multivariate analysis, marker chromosomes independently predicted poor prognosis in the AML96 trial ≤60 years. As detected by array comparative genomic hybridization, about one-third of marker chromosomes (18/49) had arisen from chromothripsis, whereas this phenomenon was virtually undetectable in a control group of marker chromosome-negative complex aberrant karyotypes (1/34). The chromothripsis-positive cases were characterized by a particularly high degree of karyotype complexity, TP53 mutations, and dismal prognosis. In conclusion, marker chromosomes are indicative of chromothripsis and associated with poor prognosis per se and not merely by association with other adverse cytogenetic features.
引用
- Bochtler T, Granzow M, Stölzel F, et al. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. Blood. 2017. PMID: 28119329. doi:10.1182/blood-2016-09-738161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。